leflunomide and Head and Neck Neoplasms
leflunomide has been researched along with Head and Neck Neoplasms in 2 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " Currently, SU101 in combination with cytotoxic agents is in late-stage clinical development for the treatment of cancers." | 1.31 | Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. ( Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM, 2000) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Stegeman, H | 1 |
| Kaanders, JH | 1 |
| Verheijen, MM | 1 |
| Peeters, WJ | 1 |
| Wheeler, DL | 1 |
| Iida, M | 1 |
| Grénman, R | 1 |
| van der Kogel, AJ | 1 |
| Span, PN | 1 |
| Bussink, J | 1 |
| Strawn, LM | 1 |
| Kabbinavar, F | 1 |
| Schwartz, DP | 1 |
| Mann, E | 1 |
| Shawver, LK | 1 |
| Slamon, DJ | 1 |
| Cherrington, JM | 1 |
Other Studies
2 other studies available for leflunomide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemor | 2013 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Div | 2000 |